CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds
Source: Benzinga ·

CG Oncology Inc. (NASDAQ:CGON) on Monday announced positive topline results from its Phase 3 PIVOT-006 trial, which Arthur Kuan, chairman, president, and CEO of CG Oncology, called a defining milestone for the company. Kuan stated that the data position cretostimogene grenadenore
Read the full story at Benzinga
Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.